Drugs / Aprotinin
Aprotinin
also known as
BAYA0128 · Trasylol · Aprotinin (bovine) · Aprotinin (synthetic) · Aprotinin biosynthetic · Aprotinin concentrated solution · Aprotinina · Aprotinine · +5 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | TRASYLOL | — | 1994-10-12 – 1998-08-28 | fda.gov ↗ |
| Approved | US (FDA) | TRASYLOL | — | 1993-12-29 | fda.gov ↗ |
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00354900 | Jul 2006 → Apr 2007 | breast cancer | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00357851 | Mar 2005 → ? | pancreatitis | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT07317050 | Jun 2026 → Mar 2030 expected | adult acute respiratory distress syndrome | Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion | Recruiting | No outcome recorded |
| Phase 3 | NCT00327379 | Feb 2006 → Mar 2007 | — | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT00306150 | Dec 2005 → Mar 2007 | — | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT00306137 | Dec 2005 → Mar 2007 | — | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT00668031 | Feb 2005 → Jan 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00396760 | Jan 2005 → Jul 2006 | aortic valve disorder | German Heart Center | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00290836 | May 2004 → Aug 2007 | — | Nycomed | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04602689 | Oct 2020 → Jul 2022 | gastric adenoma, gastric carcinoma | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT04527133 | Jun → Aug 2020 | COVID-19 | Aviron LLC | Unknown | No outcome recorded |
| — | NCT00395369 | Dec 2007 → ? | cardiac valvular defect | Soroka University Medical Center | Unknown | No outcome recorded |
| — | NCT00131040 | Jan 2003 → Jun 2005 | intermediate coronary syndrome, ischemic disease | Imperial College London | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00611845 | — | — | Bayer | No longer available | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aprotinin | “Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD” NCT04602689 ↗ |
| Known as | Aprotinin (bovine) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | Aprotinin (synthetic) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | Aprotinin biosynthetic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | Aprotinin concentrated solution | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | Aprotinina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | Aprotinine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | BAYA0128 | “Trasylol (Aprotinin, BAYA0128)” NCT00668031 ↗4“Aprotinin (Trasylol, BAYA0128)” NCT00611845 ↗ “Trasylol (Aprotinin, BAYA0128)” NCT00327379 ↗ “Trasylol (Aprotinin, BAYA0128)” NCT00306150 ↗ “Trasylol (Aprotinin, BAYA0128)” NCT00306137 ↗ |
| Known as | BAYER A 128 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | bovine aprotinin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00290836 ↗ |
| Known as | Fibrinolysis inhibitor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | RIKER 52G | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | RP 9921 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201619 ↗ |
| Known as | Trasylol | “Trasylol (Aprotinin, BAYA0128)” NCT00327379 ↗4“Trasylol (Aprotinin, BAYA0128)” NCT00306150 ↗ “Trasylol (Aprotinin, BAYA0128)” NCT00306137 ↗ “Aprotinin (Trasylol, BAYA0128)” NCT00611845 ↗ “Trasylol (Aprotinin, BAYA0128)” NCT00668031 ↗ |
| Action | Inhibit | “Aprotinin is an inhibitor of uPA activation” NCT00354900 ↗ |
| Modality | Protein / enzyme biologic | “Human fibrinogen/thrombin and bovine aprotinin” NCT00290836 ↗ |
| Route | Intravenous | “aprotinin (BAYA0128), given intravenously during your surgery” NCT00306150 ↗ |
| Target | KLKB1 | “Plasma kallikrein inhibitor” CHEMBL1201619 ↗ |
| Target | PLG | “Plasminogen inhibitor” CHEMBL1201619 ↗ |